Krystal Biotech (KRYS) Cash from Investing Activities (2016 - 2026)

Krystal Biotech has disclosed Cash from Investing Activities across 11 years of filings, most recently posting -$63.6 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$63.6 million, down 16.09% year-over-year; the trailing twelve-month figure through Mar 2026 was -$67.2 million (up 65.03% YoY), and the FY2025 annual result was -$58.4 million, up 64.26% from the prior year.
• Cash from Investing Activities came in at -$63.6 million for Q1 2026 at Krystal Biotech, down from $11.2 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $105.2 million in Q3 2023 to a low of -$83.8 million in Q4 2024.
• The 5-year median for Cash from Investing Activities is -$16.0 million (2023), against an average of -$18.6 million.
• Across the five-year window, Cash from Investing Activities plunged 7384.34% in 2022 and surged 813.5% in 2023, its largest moves.
• Krystal Biotech's Cash from Investing Activities stood at -$5.2 million in 2022, then plunged by 95.08% to -$10.2 million in 2023, then sank by 724.59% to -$83.8 million in 2024, then jumped by 113.32% to $11.2 million in 2025, then slumped by 669.59% to -$63.6 million in 2026.
• The last three Cash from Investing Activities figures came in at -$63.6 million (Q1 2026), $11.2 million (Q4 2025), and -$4.3 million (Q3 2025), per Business Quant data.